The presentation highlights TuHURA’s ongoing efforts to address primary and acquired resistance to cancer immunotherapies, a significant hurdle in current oncological treatments. The company is currently enrolling participants in a pivotal Phase 3 registration trial testing IFx-2.0, its lead innate immune agonist, as an adjunctive therapy alongside Keytruda for patients with advanced or metastatic Merkel Cell Carcinoma.
Beyond its lead candidate, the firm is advancing its pipeline with TBS-2025, a VISTA-inhibiting monoclonal antibody entering Phase 1b trials for patients with relapsed or refractory acute myeloid leukemia. TuHURA is also utilizing its Delta Opioid Receptor platform to develop bi-specific antibody drug conjugates designed to neutralize immune-suppressing cells within the tumor microenvironment. Institutional investors and stakeholders can access an archived webcast of the session through the company’s investor relations portal following the event.
Comments (0)
No comments yet. Be the first!